USRM (US Stem Cell) EBITDA Margin %: -1,875.00% (As of Dec. 2022)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell EBITDA Margin %?

US Stem Cell USRM -99.00% 12 EBITDA Margin % is -1,875.00% as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. US Stem Cell's EBITDA for the three months ended in Dec. 2022 was $-0.38 Mil. US Stem Cell's Revenue for the three months ended in Dec. 2022 was $0.02 Mil. Therefore, US Stem Cell's EBITDA margin for the quarter that ended in Dec. 2022 was -1,875.00%.

US Stem Cell  (OTCPK:USRM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

US Stem Cell EBITDA Margin % Related Terms

US Stem Cell EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for US Stem Cell's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell EBITDA Margin % Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.58 -85.03 -867.15 -1,137.81 -2,643.90

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -520.83 -4,356.52 -1,580.00 -2,835.71 -1,875.00

USRM vs NOVNQ, RGRX, NMTRQ: EBITDA Margin % Comparison

For the Biotechnology subindustry, US Stem Cell's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

US Stem Cell EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where US Stem Cell's EBITDA Margin % falls into.


USRM
12GF Score
US Stem Cell Inc USRM
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

US Stem Cell's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-2.168/0.082
=-2,643.90 %

US Stem Cell's EBITDA Margin % for the quarter that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-0.375/0.02
=-1,875.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -1,875.00% mean?
US Stem Cell (USRM) has a EBITDA Margin % of -1,875.00% as of Dec. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's EBITDA Margin % too high?
US Stem Cell's current EBITDA Margin % is -1,875.00%. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's EBITDA Margin % compare to NOVNQ and RGRX?
US Stem Cell's EBITDA Margin % of -1,875.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on US Stem Cell and its competitors. US Stem Cell's current EBITDA Margin % is -1,875.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current EBITDA Margin % of -1,875.00%. The current EBITDA Margin % is -1,875.00%. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For US Stem Cell (USRM), the current EBITDA Margin % is -1,875.00% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price